Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

Gilead’s RSV drug clears mid-stage trial

Late-stage data demonstrates GS-5806 is effective in treating the infection

- PMLiVE

No mass revolt from AZ shareholders on Pfizer takeover

Company’s decision to stand firm is applauded by investors

- PMLiVE

Epilepsy takes centre stage in UK

National Epilepsy Week aims to raise awareness of the neurological condition

- PMLiVE

PAN strengthens its team

Creative agency announces two new arrivals and three promotions

- PMLiVE

Nothing makes sense

Evolutionary theory helps us understand and adapt to the current deal-making frenzy

- PMLiVE

Cello Group buys iS Healthcare Dynamics

Marketing firm could pay more than £5m for Surrey agency

- PMLiVE

FDA clears Takeda’s vedolizumab for inflammatory bowel disease

Entyvio licensed for patients who have not responded to current therapies

- PMLiVE

GSK and Genmab’s Arzerra fails lymphoma trial

Cancer drug unable to beat Roche's MabThera in late-stage study

- PMLiVE

Boehringer launches ASCO blog to talk about lung cancer

Not Just One Disease set to cover a range of topics, including the patient journey

Novartis day

Novartis licenses Ophthotech eye drug in $1bn deal

Fovista is a potential first-in-class treatment for wet AMD

China flag thumb

Sanjing Pharma chief leaps to his death amid corruption probe

Liu Zhanbin was chairman and chief executive of the Harbin Pharmaceutical Group subsidiary

EU flag

EU approval for J&J’s hepatitis C drug

Olysio can be used in combination with Gilead’s Sovaldi

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links